The Ouvrir les yeux (OLY) association awards two prizes to young PhD graduates in science,… Read More »Young PhD: submit your application for the 2026 Ouvrir les yeux Hope Prizes without delay!
AFM-Téléthon has just published a Repères Savoir & Comprendre dedicated to mitochondrial diseases. The aim of this guide is… Read More »Publication of the Repères “Mitochondrial Diseases”
Kygevvi®, the treatment developed by UCB for thymidine kinase 2 deficiency (TK2d), has just received… Read More »TK2 Deficiency: Kygevvi® on the verge of approval in Europe
It’s not always easy to find medical and scientific publications on mitochondrial diseases. At AFM-Téléthon,… Read More »The new AFM-Téléthon quarterly watch is out!
The EuroMIT 2026 International Congress on Mitochondrial Diseases will take place from 30 May to… Read More »EuroMIT 2026 back in France, in Angers!
Kygevvi®, the treatment developed by UCB for thymidine kinase 2 deficiency (TK2d), was approved by… Read More »TK2 deficiency: first treatment approved in the United States
It’s not always easy to find medical and scientific publications on mitochondrial diseases. At AFM-Téléthon,… Read More »The new AFM-Téléthon quarterly watch is out!
The results of a large-scale study confirm the great diversity and heterogeneity of mitochondrial diseases… Read More »A (very) large French cohort of patients under the microscope
A European clinical trial shows benefits of sonlicromanol on several symptoms of diseases associated with… Read More »Encouraging results from sonlicromanol
